An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

NCT ID: NCT01676922

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

256 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/ 70 years of age
* Previously untreated metastatic colorectal cancer
* Patient considered suitable to receive chemotherapy with or without Avastin

Exclusion Criteria

* Participation in any other clinical trial or study with the exception of participation in registries
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalst, , Belgium

Site Status

Antwerp, , Belgium

Site Status

Assebroek, , Belgium

Site Status

Bonheiden, , Belgium

Site Status

Bornem, , Belgium

Site Status

Brasschaat, , Belgium

Site Status

Bruges, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Ghent, , Belgium

Site Status

Haine-Saint-Paul, , Belgium

Site Status

Hasselt, , Belgium

Site Status

Hornu, , Belgium

Site Status

Ieper, , Belgium

Site Status

Kortrijk, , Belgium

Site Status

Leuven, , Belgium

Site Status

Lier, , Belgium

Site Status

Liège, , Belgium

Site Status

Mechelen, , Belgium

Site Status

Mons, , Belgium

Site Status

Mont-godinne, , Belgium

Site Status

Namur, , Belgium

Site Status

Ostend, , Belgium

Site Status

Oudenaarde, , Belgium

Site Status

Roeselare, , Belgium

Site Status

Ronse, , Belgium

Site Status

Seraing, , Belgium

Site Status

Sint-Niklaas, , Belgium

Site Status

Tongeren, , Belgium

Site Status

Turnhout, , Belgium

Site Status

Verviers, , Belgium

Site Status

Wilrijk, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML27768

Identifier Type: -

Identifier Source: org_study_id